Mologic

Home/Mologic

About Mologic

This author has not yet filled in any details.
So far Mologic has created 14 blog entries.

Preliminary clinical performance data for professional use COVID-19 rapid diagnostic test

By |2020-05-07T13:17:24+01:00May 1st, 2020|

Mologic is pleased to announce that following rigorous independent assessment by St George’s, University London and Liverpool School of Tropical Medicine, our point-of-need, professional use, rapid diagnostic test (RDT) for COVID-19 has achieved preliminary clinical performance data of 98% sensitivity at days 14-21 and specificity of 96%. The test [...]

Mologic awarded c.£1 million by UK government to develop rapid diagnostic test for COVID-19

By |2020-04-06T16:10:57+01:00March 6th, 2020|

Grant awarded as part of UK government’s £46 million international COVID-19 prevention and research package Test will support global efforts to prevent further spread of COVID-19 by enabling rapid diagnosis at the point-of-need Funding will also initiate Mologic’s research for novel vaccine candidates Bedfordshire, UK, 6th March 2020: Mologic [...]

Mologic and Institut Pasteur de Dakar launch accelerated programme to develop rapid diagnostic test for Ebola

By |2020-04-06T16:09:57+01:00February 25th, 2020|

Project aims to facilitate early diagnosis and support efforts to stop the Ebola Virus Disease epidemic Rapid point-of-need test critical to boosting surveillance and response to global viral outbreaks Partnership builds on BIOASTER’s early R&D during the 2014-2016 Ebola outbreak   Bedfordshire, UK, 25 February 2020: Mologic Ltd, a [...]

BIOASTER Awarded Grant for the Development of Rapid Diagnostics for Neglected Tropical Diseases

By |2020-04-06T16:08:17+01:00January 9th, 2020|

BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation to develop Onchocerciasis advanced rapid diagnostic with Mologic Ltd Lyon, January 07th, 2020 BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, today announced it has received a grant in the field of diagnosis of Neglected [...]

Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system

By |2020-04-06T16:07:22+01:00November 20th, 2019|

Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD Headstart is a non-invasive self-test that detects lung biomarkers in the urine Observational, multi-centre validation trial carried out in collaboration [...]

Mologic pushing the boundaries of high sensitivity lateral flow technology – Charlton Morris Life Science

By |2020-04-06T16:03:50+01:00October 7th, 2019|

Being recognised as a company pushing the boundaries of high sensitivity lateral flow technology, Charlton Morris Life Science recently visited Mologic to speak with our Co-Founder and Chief Scientific Officer, Professor Paul Davis, the originator of the Clearblue pregnancy test, the world’s first commercial application of lateral flow technology. [...]

Mologic Developing Sepsis Test Using Multimarker Lateral Flow Technology

By |2020-04-06T16:02:36+01:00September 20th, 2019|

Sep 20, 2019 | Leo O'Connor NEW YORK – Mologic is developing a multimarker point-of care diagnostic test using lateral flow technology that it anticipates launching in Europe next year. The diagnostic test, which is being evaluated as part of a University College London Hospitals (UCLH) study, is part [...]

Mologic and University College London Hospitals collaborating in major clinical trial for early detection of sepsis

By |2020-04-06T16:00:12+01:00September 13th, 2019|

Study aims to develop a rapid point-of-care diagnostic based on multiple biomarkers to detect emergent sepsis Observational study led by Mervyn Singer, Professor of Intensive Care Medicine and Dr David Brealey, Consultant in Intensive Care Bedfordshire, UK, 13 September 2019: Mologic Ltd, a leading developer of lateral flow and [...]

Mologic achieves breakthrough in ultra-sensitive point-of-care diagnostics and develops new platform technology

By |2020-04-06T15:53:13+01:00May 7th, 2019|

Visually-read device delivers up to 1,000-fold improvement in sensitivity to support surveillance and elimination efforts of global epidemics Since 2016, the Bill & Melinda Gates Foundation has committed $9.7 million to establish and accelerate the CARD technology programme Bedfordshire, UK, 7 May 2019: Mologic Ltd, a leading developer of [...]

Load More Posts